10-Q
Quarterly Report
10x Genomics, Inc.
TXG
NASDAQ
CIK: 1770787
File #: 001-39035
Balance Sheet
39 line items · 2 periods
XBRL
| Item | Mar 31, 2025 | Dec 31, 2024 |
|---|---|---|
Assets | ||
Current assets: | ||
Cash and cash equivalents | 377,061,000 | 344,067,000 |
Marketable securities | 49,844,000 | 49,335,000 |
Accounts receivable, net | 52,549,000 | 87,862,000 |
Inventory | 74,710,000 | 83,107,000 |
Prepaid expenses and other current assets | 25,566,000 | 20,016,000 |
Total current assets | 579,730,000 | 584,387,000 |
Property and equipment, net | 246,087,000 | 252,648,000 |
Operating lease right-of-use assets | 55,577,000 | 57,290,000 |
Goodwill | 4,511,000 | 4,511,000 |
Intangible assets, net | 15,192,000 | 15,671,000 |
Other noncurrent assets | 2,296,000 | 4,129,000 |
Total assets | 903,393,000 | 918,636,000 |
Liabilities and stockholders’ equity | ||
Current liabilities: | ||
Accounts payable | 10,068,000 | 12,909,000 |
Accrued compensation and related benefits | 21,957,000 | 33,615,000 |
Accrued expenses and other current liabilities | 45,483,000 | 41,165,000 |
Deferred revenue | 20,949,000 | 20,658,000 |
Products and Services, Excluding Grant Revenue | 20,900,000 | — |
Operating lease liabilities | 9,443,000 | 9,286,000 |
Total current liabilities | 107,900,000 | 117,633,000 |
Operating lease liabilities, noncurrent | 70,631,000 | 73,327,000 |
Deferred revenue, noncurrent | 12,569,000 | 12,513,000 |
Other noncurrent liabilities | 5,398,000 | 5,029,000 |
Total liabilities | 196,498,000 | 208,502,000 |
Stockholders’ equity: | ||
Preferred stock | 0 | 0 |
Common stock | 2,000 | 2,000 |
Additional paid-in capital | 2,208,665,000 | 2,177,672,000 |
Accumulated deficit | (1,501,405,000) | (1,467,047,000) |
Accumulated other comprehensive loss | (367,000) | (493,000) |
Total stockholders’ equity | 706,895,000 | 710,134,000 |
Common Stock | 2,000 | 2,000 |
Additional Paid-in Capital | 2,208,665,000 | 2,177,672,000 |
Accumulated Deficit | (1,501,405,000) | (1,467,047,000) |
Accumulated Other Comprehensive Income (Loss) | (367,000) | (493,000) |
Total liabilities and stockholders’ equity | 903,393,000 | 918,636,000 |